Request More Information
Clinical Test Menu
In the United States, colorectal cancer (CRC) is the third most common cancer and the third leading cause of tumor associated death in men and women. CRC is a heterogeneous disease defined by different receptor tyrosine kinase (RTK) activation, signaling through phosphatidylinositol 3-kinase (PI3K)/AKT and RAS/MAP2K pathways. A comprehensive signaling pathway profile analysis may be a critical guide for selecting effective clinical strategies for targeted drugs in combinations or in sequential regimens.
The top row illustrates “Molecular” DAB or mDAB, which were generated from the IF images (data not shown), and demonstrates equivalent staining to the standard IHC DAB images in CRC tissues.
The key RTKs (EGFR, HER2, HER3 and cMET) and downstream signaling proteins (PI3K, PTEN, pAKT and pERK1/2) were characterized in CRC tumors by MultiOmyx hyperplexed IF staining (20X). Two distinctive patterns of biomarker expression are shown, indicating activation of different signaling pathways.
Hyperplex Immunofluorescence (IF) Assay
MultiOmyx Integrated multi “Omic” assays